Neuropathix is a pioneer in breakthrough therapeutics targeting neuroinflammation, healthspan and neuropathic pain. Currently conducting R&D at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA.
Our Identity: Pioneers in Non-Opioid Therapeutics
Neuropathix is a biopharmaceutical company focused on discovering, developing and commercializing breakthrough therapeutics targeting neuroinflammation, healthspan and neuropathic pain to treat patients with a variety of unmet medical needs. Since 2010, we have been principally involved in the research and development of synthetic cannabidiol (CBD) inspired therapeutics through pre-clinical drug discovery and development processes.
From 2012 to 2019, the Neuropathix subsidiary Kannalife Sciences, Inc. held an exclusive license with National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”). Kannalife has also developed its own patented molecules lead by KLS-13019 featured in Sports Illustrated and awarded U.S. Patent #9611213, “Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy” and U.S. Patent #10004722, “Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols.”
Our Vision & Legacy
We focus on the intersection of neurological health and pain management. Our ultimate goal is to leave a legacy of treating the millions suffering from:
- Neuropathic Pain & Chronic Inflammation: Providing relief without the side effects of traditional analgesics.
- Chemotherapy Complications: Addressing the root causes of peripheral neuropathy.
- Opioid Addiction: Offering alternatives that reduce cravings and withdrawal symptoms.
- Aging-Related Pathways: Mitigating the effects of neuroinflammation and mitochondrial dysfunction.
A Foundation of Strategic Partnerships
Our progress is validated and accelerated by a global network of leading scientific and financial partners:
- NIH HEAL Initiative: Awarded a $3.3M grant for peripheral neuropathy research and IND-enabling studies.
- The Michael J. Fox Foundation: Awarded a $1.5M grant specifically for Parkinson’s Research, partnership with University of Würzburg and Atuka Inc.
- Temple University School of Medicine: Collaborative research and peer-reviewed studies on animal efficacy.
- Prevail Partners: A life sciences VC with a forward capital commitment.
- Purisys™: Partners in proprietary, scaled-up CMC (Chemistry, Manufacturing, and Controls).
The Science of Better Health
Our platform focuses on two core objectives to improve cellular longevity:
- Reducing the Pain Footprint: We target the GPR55 receptor—a pro-inflammatory “early mediator”—to stop neuroinflammation before it cascades.
- Improving Cellular Healthspan: Our compounds promote Mitochondrial Resilience by regulating calcium exchange (NCX-1), helping to arrest the acceleration of aging processes.
Validated Scientific Discovery
Neuropathix’s lead candidate, KLS-13019, is backed by a decade of rigorous validation:
- 9 Peer-Reviewed Publications: Featured in journals such as The Journal of Molecular Neuroscience, The British Journal of Pharmacology and ASPET.
- Global Patent Protection: A first-in-class New Chemical Entity (NCE) with worldwide intellectual property coverage.
- Superior Bioavailability: Demonstrated 67% oral bioavailability and the ability to penetrate the blood-brain barrier.
